ApiJect Systems, Corp., Announces Appointment of Global Branding Leader, Craig Cohon as Chief Strategy Officer

STAMFORD,Conn.,March 19,2021 --ApiJect Systems,Corp.,a medical technologypublic benefit corporationthatismaking prefilled injectorstodeliver medicines and vaccines with enormous speed,scale,and efficiency,announced today that Craig Cohonhas been appointed Chief Strategy Officer.

Craig Cohon,Chief Strategy Officer at ApiJect Systems,Corp.

London-basedMr.Cohonhasservedsince May 2020asGlobal Advisorto ApiJect.Withan extensive and eclectic mix of global business experience,he bringsspecialskill inpioneeringstrategies,expanding into new markets andleveragingnew platforms thatare especially timely in a fast-changing businessand public healthenvironment.­­­

Mr.Cohonspent 14 yearsin executive leadership with The Coca Cola Company,spearheadingitsentry intoRussiain 1991 and leading brandwork forCoca-Cola globally. He also spent close to a decadeowning andleading the Cirque du Soleil business in Russia.For the past 20 yearsCohonhas been passionate aboutsustainability,andhas led severalentrepreneurialventures. He was Chairmanfor 10 yearsof Worn Again,the world's first closed loop textile recycling company,now majority-owned by H&M.Healsospent eight years running an international development advisory firm that built businesses in India and Africa,includingFirst Energy,an alternative energy company providingcommercial cooking to over a million kitchensin India,as well as Reuters Market Light,a technologycompany that improved productivity and profitability for over 3.3 million Indian farmers. 

In his new roleatApiJect,Mr.Cohonwill lead the company's strategic and brand development in the U.S. and abroad. Having worked,livedand travelledacross more than 100 countries,Mr.Cohonpossesses strong relationships globally that will facilitateApiJect'sjump into new markets as it pursues its mission to serve global health. Mr.Cohonwill also play a central rolein guiding the company's efforts to introduce its high-volume,low-cost,easily administered single-doseprefilledinjectorsand related platforms into the world's response to the COVID-19 pandemic and other future bio-emergencies.

In welcoming Mr.Cohon,ApiJect CEO Franco Negron,commented: "ApiJect is moving rapidly to meet the demands of its mission. This is a time when everyone in the company is asked to wear many hats and having someone like Craig who truly has his hands in everythingsignificant to our progressgoingforward isa huge value-add for the company."

Mr. Negron continued: "Craig is a multilingual,multi-dimensional and multi-talented leader with proven success guiding brands and strategic direction. He understands how to frame,articulate and implement business strategy in ways that speak to investors,consumers,and industry and national leaders. Craig has pushed and pulled global brands into new markets,investing in cutting-edge ideas and business platforms along the way. I cannot overstate the value he has added as an advisor over the last ten months and how excited I am to have him as a full-time presence onApiJect'sExecutive Leadership team."

ApiJect Co-Founder and Chairman,Jay Walker said: "Craig as our full-time strategy leader further elevates our opportunity to grow as a significant presence in global health.  His track record of executing in different markets and regions,each with their own culture and market characteristics,will help ApiJect to effectively pursue our mission across the globe."

Mr.Cohoncommented: "I am deeply moved byApiJect'smission to make injectable medicine safe,effective and easily available in the United States and globally. I am joining ApiJect as it transitions from exciting start-up to established industry game-changer. This presents a wonderful opportunity to firmly root that mission in the company's strategic direction. I look forward to the adventure ahead."

ABOUT APIJECT SYSTEMS,CORP.

ApiJect Systems,Corp. is a medical technology company that revolutionizes how the world manufactures and delivers injectable medicines and vaccines.

The ApiJect technology platform brings together simple,interconnectable components to create scalable drug delivery devices for U.S. and global markets. At the center of these devices is the aseptic and cost-effective Blow-Fill-Seal (BFS) fill-finish process. And,by using a modular manufacturing approach,these devices can be produced in clinical or commercial scale by ApiJect or the drug manufacturer.

Our first device,the single-dose ApiJect Prefilled Injector,allows a healthcare professional to twist a pen needle-style hub onto a BFS container — creating a simple,scalable prefilled syringe. ApiJect is working with several vaccine pharmaceutical companies to conduct the testing and regulatory reviews of COVID-19 vaccines in the ApiJect Prefilled Injector. ApiJect has submitted its needle hub device for a pre-submission FDA review and anticipates the filing of its drug container with COVID-19 vaccine as part of a review submission by each ofApiJect'sCOVID-19 vaccine partners.ApiJect'sPrefilledInjector will be ready for patient distribution as soon as it receives FDA approval.

In 2020,ApiJect was awarded a $138 million contract from the U.S. Department of Defense,in cooperation with the U.S. Department of Health and Human Services,to create a high-volume domestic capacity to supply prefilled injectors. The U.S.-based facility that ApiJect has developed through this emergency program has the capacity to provide approximately 45 millionPrefilledInjectors per month to America's population through 2021.

ApiJect has also recently been approved by the U.S. International Development Finance Corporation for a $590 million loan to construct a multi-facility campus enabling the U.S. to more quickly package high volumes of injectable medicines and vaccines in the event of a national emergency,beginning with COVID-19. Located in Research Triangle Park,North Carolina,this 1.2 million square foot campus will be home to the ApiJect Gigafactory,is one of the world's largest pharmaceutical fill-finish facilities. The campus is expected to have an annual production capacity of up to 3 billion single-dose prefilled injectors.

ApiJect,along with the U.S. Department of Health and Human Services,is a founding member of the RAPID Consortium,a public-private partnership dedicated to giving the U.S. and the world the surge capacity it needs for drug packaging to address future pandemics and bio-emergencies.

Learn more about ApiJect atwww.apiject.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of applicable securities legislation. All statements,other than statements of historical fact,included in these materials that address activities,events or developments that ApiJect expects,believes or anticipates will or may occur in the future are forward-looking statements. The words "believe","expect","may","estimates","will","anticipate","plan","intend","foresee","should","would","could",or other similar expressions are intended to identify forward-looking statements,which are generally not historical in nature. However,the absence of these words does not mean that the statements are not forward looking. Without limiting the generality of the foregoing,forward-looking statement contained in this press release specifically include the expectations of plans,strategies,and objectives of ApiJect. Such statements are subject to a number of assumptions,risks and uncertainties,many of which are beyond the control of ApiJect,which may cause actual results to differ materially from those implied or expressed by the forward-looking statements.